Oh, Tranexamic Acid, How We’ve Misjudged Thee

Once upon a time, in the land of medical research, there was a substance called tranexamic acid (TXA). It was whispered in the hallowed halls of hospitals that TXA might be a sneaky little devil, luring doctors in with promises of reduced bleeding only to spring the trap of venous thromboembolic events (VTEs) on unsuspecting patients. But lo and behold, a group of intrepid researchers decided to challenge the narrative and embarked on a quest to clear TXA’s besmirched name.

Armed with the power of three whole databases, our heroes sifted through the sands of time (or at least the sands of non-traumatic cranial neurosurgery literature) to find out if TXA was really the villain it was made out to be. They gathered an army of twenty-eight studies, featuring a cast of characters including brain tumors, aneurysmal subarachnoid hemorrhage (aSAH), and the skull-shaping adventures of craniosynostosis.

In the epic battle against blood loss during brain tumor surgery, TXA emerged as a shining knight, reducing the red tide without so much as a hint of VTE or seizure. Alas, in the realm of aSAH, TXA’s magic wand failed to banish the specter of vasospasm, and it shrugged its shoulders at long-term neurological outcomes. But fear not, for in the land of tiny humans with craniosynostosis, TXA proved its worth once again, slashing blood loss like a hero. Just remember, kids, low doses are the way to go because who really knows what high doses could do?

In conclusion, let’s all raise our goblets to TXA, the misunderstood potion that’s actually a pretty decent ally in the fight against blood loss. It’s ready to serve in a wide array of neurosurgical theatrics, across a diverse ensemble of patients. So next time you hear a scary story about TXA, maybe take it with a grain of salt—or better yet, a pinch of evidence-based medicine.